AstraZeneca Announced Earlier It Entered Exclusive Global License Agreement With Dizal For Novel Oral EGFR Inhibitor Zegfrovy For Lung Cancer; AstraZeneca To Pay $600M Upfront, Up To $900M In Milestones, Plus Royalties

AstraZeneca PLC

AstraZeneca PLC

AZN

0.00
AstraZeneca Announced Earlier It Entered Exclusive Global License Agreement With Dizal For Novel Oral EGFR Inhibitor Zegfrovy For Lung Cancer; AstraZeneca To Pay $600M Upfront, Up To $900M In Milestones, Plus Royalties
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.